NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Emergent Biosolutions Inc is a small cap company (market value between $300 million and $2 billion) in the Drug Manufacturers - Specialty & Generic industry.
Emergent Biosolutions is a life sciences company providing preparedness and response solutions for public health threats including chemical, biological, radiological and nuclear incidents, emerging infectious diseases, and opioid overdose emergencies. The company operates three segments: Commercial Products selling naloxone treatments; MCM Products serving government customers; and Services offering contract manufacturing to external clients.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Emergent Biosolutions Inc stock.
Undervalued: intrinsic value $33.89 per share, market price $6.81, margin of safety 79.9% (as of 2026-10-30).
Discounting its cash flows at 8.5% (average of 2 methods) values the shares at $33.89; the price of $6.81 is 80% below that value, and 76% of that value comes from beyond year five.
Leak Score: 62/100 on 11 of 12 signals (Faint Leak).
17 more funds hold it; the full list is part of the paid plan.
All 84 Drug Manufacturers - Specialty & Generic stocks
EBS is undervalued (as of the 2026-10-30 close). Discounting its cash flows at 8.5% (average of 2 methods) values the shares at $33.89; the price of $6.81 is 80% below that value, and 76% of that value comes from beyond year five.
$33.89 per share (as of the 2026-10-30 close), against a market price of $6.81. That is a margin of safety of 79.9%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
62 out of 100, which we rate "Faint Leak", on 11 of 12 value investing signals.